Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Company profile updated October 15, 2026.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: